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Background: Keloid is a benign dermal tumor characterized by proliferation of dermal 
fibroblasts and overproduction of extracellular matrix (ECM). Nuclear factor kappa B 
(NF-κB) plays an important role in regulation of inflammation, immune response and 
cell proliferation. Activation of the NF-κB pathway is thought to be closely linked to 
abnormal cell proliferation and ECM production in keloid fibroblasts. 
Objective: This study was set out to investigate the effects of a novel selective NF-κB 
inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on keloid fibroblasts. 
Methods: Primary normal and keloid dermal fibroblasts were used for this study. 
NF-κB activity was assessed by DNA-binding assay and immunohistochemistry. The 
effect of DHMEQ was evaluated by cell viability, cell growth and type I collagen 
accumulation. 
Results: Basal NF-κB activity was constitutively elevated in keloid fibroblasts, 
indicating that this pathway is involved in keloid pathogenesis. DHMEQ markedly 
reduced cell proliferation and type I collagen accumulation in keloid fibroblasts. 
Conclusion: The inhibition of NF-κB by DHMEQ may be an attractive therapeutic 
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approach for keloids. 
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1. Introduction 
   Keloids are fibrous overgrowths due to abnormal wound healing process after skin 
injury. They are characterized by proliferation of dermal fibroblasts and overproduction 
of extracellular matrix (ECM). Although keloid is a benign dermal tumor, its 
management is one of the most challenging clinical problems. Keloids do not regress 
with time and surgical excision alone results in a high rate of recurrence. Various 
conservative therapies have been attempted, but definite and effective treatment has not 
yet been established [1,2]. 
   The ubiquitous nuclear factor kappa B (NF-κB) transcription factor regulates 
expression of a wide spectrum of genes involved in immune and inflammatory response,  
cellular proliferation and apoptosis [3-6]. Activation of the NF-κB pathway is 
implicated in a diverse range of diseases including asthma, rheumatoid arthritis, 
inflammatory bowel disease and human cancer. NF-κB-targeted therapy has been 
attempted in these diseases and appears to be an effective and useful modality [7]. 
Recently, it has been reported that the NF-κB pathway is also activated in keloid 
fibroblasts [8]. 
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   The NF-κB family is comprised of NF-κB1 (p50/p105), NF-κB2 (p52/p100), p65 
(RelA), RelB and c-Rel. Although many dimeric forms of NF-κB have been identified, 
the most prevalent activated form of NF-κB is the heterodimer consisting of DNA 
binding subunit p50 and transactivation subunit p65. In unstimulated cells, NF-κB is 
sequestered in the cytoplasm in an inactive form by its inhibitor proteins called 
inhibitors of κB (IκBs). A variety of stimuli including pro-inflammatory cytokines, 
mitogens, viral infection, ultraviolet radiation and free radicals activate a large complex 
termed IκB kinase (IKK), which phosphorylates IκB protein, resulting in its 
ubiquitination and proteosomal degradation. Then, freed NF-κB translocates to the 
nucleus and activates transcription of a vast number of target genes. Some of the 
proinflammatory cytokines that might have a role in keloid pathogenesis such as 
interleukin 1 (IL-1) and tumor necrosis factor α (TNF-α) are stimulated by NF-κB. 
These cytokines can directly activate the NF-κB pathway, thus establishing a positive 
autoregulatory loop. Hence, the blockade of the NF-κB pathway could be an attractive 
strategy for the treatment of keloids. 
   A novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ), a 
6 
derivative of the antibiotic epoxyquinomicin C [9], has been found to specifically 
inhibit TNF-α-induced nuclear translocation of NF-κB [10]. Treatment with DHMEQ 
showed an anti-inflammatory effect on rheumatoid arthritis and renal inflammation in 
animals. DHMEQ also demonstrated potent anti-cancer activity in various in vitro and 
in vivo models such as prostate carcinoma, breast carcinoma, thyroid carcinoma and 
hematologic malignancies without any apparent toxic side effects [11,12]. 
   In the present study, we report that DHMEQ is effective in blocking growth and 
type I collagen accumulation in keloid fibroblasts, supporting the concept that inhibitors 
of the NF-κB pathway may be useful therapeutic agents for keloids. 
 
 
2. Materials and methods 
2. 1. Reagents 
   Stock solutions of racemic DHMEQ (20 mg/ml) were prepared in dimethylsulfoxide 
(DMSO) and stored at -20°C until use. Antibodies were obtained from the following 
sources: anti-p65 polyclonal and β-actin monoclonal from Santa Cruz Biotechnology 
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(Santa Cruz, CA, USA); anti-collagen type I polyclonal from Rockland 
Immunochemicals (Gilbertsville, PA, USA); anti-Hsp47 monoclonal from Stressgen 
Assay Designs (Ann Arbor, MI, USA); anti-Poly ADP ribose polymerase (PARP) 
polyclonal and secondary horseradish peroxidase (HRP)-conjugated anti-rabbit/mouse 
IgG from Cell Signaling Technology (Beverly, MA, USA). 
 
2. 2. Cell culture 
   Keloid tissue samples were obtained from four different Japanese patients at the 
time of surgery. Four normal skin tissue samples were obtained from four different 
Japanese volunteers. No comorbid systemic disorders such as diabetes and cancers, nor 
taking drugs known to influence the transcriptional response of cells, were identified. 
All experiments were performed after obtaining hospital ethical committee approval. 
Informed consent was obtained from each individual. The profile of each sample is 
summarized in Table. 1. All keloid tissue specimens were pathologically examined to 
confirm the diagnosis. 
   Primary cultures of dermal fibroblasts were established as previously described [13]. 
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Explants were maintained in Dulbecco's modified Eagle's medium supplemented with 
10% fetal bovine serum and 1% (w/v) penicillin/streptomycin in 5% CO2 humidified 
atmosphere at 37°C. Fibroblasts at passages of 3 to 8 were used in this study. We did 
not observe any alteration in cell shape, growth rate and sensitivity to DHMEQ until 
passage 8. 
 
2. 3. DNA-binding assay 
   Nuclear extracts were prepared as described previously [14]. The multiwell 
colorimetric assay for phoshorylated p65 protein was performed using the Trans-AM 
NF-κB p65 Transcription Factor Assay Kit (Active Motif North America, Carlsbad, CA, 
USA). Briefly, equal amount of nuclear extracts were incubated in 96-well plates coated 
with immobilized oligonucleotide containing a NF-κB consensus binding site. NF-κB 
binding to target oligonucleotides was detected by incubation with primary antibodies 
against the p65 subunit and HRP-conjugated secondary antibody. For quantification of 
activity, optical densities were measured at 450 nm with a microplate reader 
ImmunoMini NJ-2300 (System Instruments, Tokyo, Japan).  
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2. 4. Immunohistochemistry 
   Immunohistochemical detection of NF-κB p65 subunit was done using 
immunoperoxidase technique. Briefly, tissue sections from paraffin-embedded tissue 
were deparaffinized in xylene and dehydrated in alcohol. Slides were then subjected to 
antigen retrieval by four times of 5-min microwave heating in 10 mM sodium citrate 
(pH 6.0) and cooled at room temperature. Endogenous peroxidase was blocked by 
incubation for 10 minutes with 3% hydrogen peroxidase in deionized water. 
Nonspecific binding was blocked with 1% BSA for 10 minutes. Sections were then 
incubated overnight at 4°C with anti-p65 polyclonal antibody. Biotinylated secondary 
antibody was applied, and sections were incubated with avidin-biotin peroxidase 
complex, developed with 3, 3’-diaminobenzidine substrate and counterstained with 
hematoxylin. Positive cells were counted in six high power fields (magnification x400) 
by two independent investigators in a blinded fashion. 
 
2. 5. Cell viability assay 
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   Cultures were established in 96-well flat-bottomed microtiter plates (Nalge Nunc 
International, Tokyo, Japan). Cells were counted, plated at 5×103 cells/well (100 μL) 
and incubated for 24 hours before treatment. Solutions containing DHMEQ were added 
to each well in 10 μL of medium at various concentrations, with 6 wells used for each 
concentration. In control wells, solution of DMSO was added. Cells were incubated at 
37°C for 24 hours, and then water-soluble tetrazolium salt (WST)-based assay was done 
as follows: medium was changed (100 μL/well), and 10 μL of Cell Counting Kit-8 
solution (Dojindo, Kumamoto, Japan) were added to each well and incubated for 2 
hours at 37°C. Optical densities were measured at 450 nm in a microplate reader 
ImmunoMini NJ-2300. 
 
2. 6. Cell proliferation assay 
   Cell suspensions (100 μL, 1×103 cells/well) were added to each well of 96-well 
flat-bottomed microtiter plates and incubated for 24 hours before treatment. Solutions of 
DHMEQ were added to each wells at the concentration of 5 μg/ml or 10 μg/ml. After 
24, 48, 96 hours exposure to the drug, WST-based assay was done as described above. 
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2. 7. Western blotting 
   Cells were washed twice with ice-cold PBS, collected in 1 ml PBS and centrifuged 
for 3 minutes at 3,000 rpm. For total cell extracts, each pellet was resuspended in 200 
μL of a buffer containing 20 mM HEPES (pH 7.5), 0.35 M NaCl, 20% glycerol, 1% 
NP40, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA and protease inhibitor cocktail 
(Roche Diagnostics, Basel, Switzerland). After incubated for 15 minutes on ice, lysates 
were centrifuged for 15 minutes at 15,000 rpm at 4°C, and the supernatants were 
collected and stored at -80°C. To obtain the secreted ECM proteins, culture media was 
collected and concentrated using a Speed Vac CVE 200D (EYELA, Tokyo, Japan). 
Protein concentrations were determined with a Bichinonic Acid Assay Kit (Sigma, St 
Louis, MO, USA). Equal amount of proteins were resolved by SDS- PAGE and 
transferred onto polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA, 
USA) by semidry blotting. After incubation with appropriate primary antibody, the 
antigen-antibody complexes were visualized using HRP-conjugated secondary antibody 
and enhanced chemiluminescence reagents (Amersham, Piscataway, NJ, USA). For 
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quantitation of band intensities, image analysis was done with Gel-Pro Analyzer 
software (Media Cybernetics, Bethesda, MD, USA). 
 
2. 8. Statistical analysis 
   All data were expressed as the mean±SD. Differences between groups were 
examined for statistical significance with the Mann-Whitney U test and/or one-way 
ANOVA followed by Fisher’s PLSD where appropriate. A p value not exceeding 0.05 




3. 1. NF-κB is activated in keloid fibroblasts 
   We first examined basal DNA-binding activity of NF-κB in normal and keloid 
fibroblasts. For this purpose, primary fibroblasts derived from four different patients 
and healthy volunteers were established. Consistent with the previous report [8], there 
was elevated basal level of NF-κB activity in keloid fibroblasts as compared to normal 
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fibroblasts (Fig. 1). 
   To further confirm activation of the NF-κB pathway in keloids, we performed 
immunohistochemistry using keloid tissue specimens. As shown in Fig. 2, intense 
immunoreactivity for p65 in both cytoplasm and nucleus was observed in keloid tissue 
(Fig. 2B, D). By contrast, normal skin tissue specimen showed very weak 
immunoreactivity (Fig. 2A, C). The number of positive cells in keloid tissue was 
significantly higher than that in normal tissue (Fig. 2E). Note that epidermis of the 
keloid tissue section also showed diffuse and intense immunostaining for p65, 
suggesting that NF-κB is also activated in keloid keratinocytes. Thus, activation of 
NF-κB in keloids were confirmed both in vitro and in vivo. 
 
3. 2. DHMEQ suppresses NF-κB in keloid fibroblasts 
   To examine the pharmacological effect of DHMEQ on primary normal and keloid 
fibroblasts, DNA-binding assay was performed. The addition of DHMEQ was found to 
suppress basal DNA binding of the p65 protein in both normal and keloid fibroblasts; 
however, keloid fibroblasts were more sensitive to DHMEQ (Fig. 3). Although the 
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mean basal NF-κB activity was approximately 1.7-fold higher in keloid fibroblasts 
compared to normal fibroblasts (p<0.05), it decreased to the same level as in normal 
fibroblasts after treated with 5 μg/ml of DHMEQ. This result suggests that DHMEQ 
successfully suppressed NF-κB activity in keloid fibroblasts. 
 
3. 3. Cytotoxic effect of DHMEQ 
   To determine the cytotoxic effect of DHMEQ, normal and keloid fibroblasts were 
treated with various concentrations of DHMEQ, and cell viability was estimated by 
WST assay. The response varied between the cells obtained from different individuals, 
but viability of keloid fibroblasts was decreased stronger than that of normal fibroblasts 
at same concentration of DHMEQ (Fig. 4). Average ED50 was calculated to be 27.3±4.0 
μg/ml for normal fibroblasts and 20.1±2.9 μg/ml for keloid fibroblasts (p<0.05). To 
explore whether the cytotoxic effect of DHMEQ was due to apoptosis, we performed 
Western blotting for PARP. Cleavage of PARP along with DNA laddering and 
membrane inversion are known to be the most characteristic events in apoptosis. As 
shown in Fig. 4B, apparent PARP cleavage was detected from the concentration of 25 
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μg/ml in both normal and keloid fibroblasts. DHMEQ did not induce any cytotoxic 
effect at lower than 15 μg/ml in normal fibroblasts. Thus, we used DHMEQ at the 
concentration of 5 and 10 μg/ml for further experiments. 
 
3. 4. Effect of DHMEQ on cell growth 
   We next examined the effect of DHMEQ on cell proliferation. Cells were treated 
with DHMEQ at the concentration of 5 or 10 μg/ml and cultured for up to 4 days. 
Although the response to DHMEQ varied between the cells, most of normal fibroblasts 
were affected only slightly (Fig. 5A), and the DHMEQ treatment had no significant 
influence on average cell proliferation of normal fibroblasts (Fig. 5B). By contrast, the 
growth of keloid fibroblasts was significantly inhibited compared to the normal 
fibroblasts (Fig. 5A, B) in a dose dependent manner. It has been reported that DHMEQ 
causes only a transient NF-κB inhibition [15], but DHMEQ inhibited the growth of 
keloids during the observed period. 
 
3. 5. Effect of DHMEQ on type I collagen accumulation 
16 
   To study the effect of DHMEQ on ECM, we performed Western blotting to assess 
both secreted and cellular type I collagen. The culture media or whole cell lysates were 
used for this purpose. After 24 hours treatment with DHMEQ, expression of both 
secreted and cellular type I collagen was reduced in keloid fibroblasts in a dose 
dependent manner, while normal fibroblasts showed no decrease (Fig 6). 
   HSP47 is a collagen-specific molecular chaperone that interacts with procollagen 
during the process of folding, assembly and transport from the endoplasmic reticulum 
[16]. The expression of HSP47 is closely correlated with that of collagen in fibrotic 
disorders including keloids. However, the exact mechanism of how HSP47 is regulated 
remains unclear. Therefore, we performed western blotting to investigate whether 
DHMEQ affects HSP47 expression. Consistent with a previous report [17], very strong 
immunoreactive bands at 47 kDa were detected in all keloid samples compared to 
normal samples. However, DHMEQ treatment did not show any effect on HSP47 






   In the present study, we demonstrated the constitutive elevation of the NF-κB 
activity in keloid fibroblasts in both DNA-binding assay (Fig. 1) and 
immunohistochemical analysis (Fig. 2), suggesting that this signaling pathway may play 
a role in keloid pathogenesis. Since NF-κB family protein is found in virtually all cell 
types, normal fibroblasts are also affected by DHMEQ. However, cell viability assay 
showed no significant cell number decrease at lower than 15 μg/ml of DHMEQ in 
normal fibroblasts (Fig. 4A), and also cell proliferation assay showed that only keloid 
fibroblasts displayed significant growth reduction at low doses of DHMEQ (Fig. 5). 
Presumably, this could be due to low basal NF-κB activity in normal fibroblasts since 
low concentration of DHMEQ hardly affected NF-κB activity in normal fibroblasts but 
strongly reduced in keloid fibroblasts (Fig. 3). These results suggest that survival and 
growth of keloid fibroblasts are largely dependent on high basal activity of NF-κB 
signaling. 
   Two mechanisms can be considered for how DHMEQ suppresses proliferation of 
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keloid fibroblasts. One is through down-regulation of genes involved in cell cycle 
progression. Cyclins D1 and D2 are downstream targets of NF-κB pathway and directly 
regulate G1-S transition [18]. Thus, the down-regulation of those cyclins by DHMEQ 
may lead to growth arrest in keloid fibroblasts. The other is through suppression of 
inflammatory cytokine IL-6. IL-6 is also a downstream target of NF-κB pathway and is 
involved in keloid pathogenesis. Because IL-6 peptide induces proliferation of 
fibroblasts [19], inhibition of this cytokine by DHMEQ may also lead to decreased 
proliferation of keloid fibroblasts. 
   The effect of NF-κB activation on type I collagen, a principal component of 
excessive matrix in keloids, seems to be complicated. Type I collagen is a heterotrimeric 
protein composed of two α1 chains and one α2 chain encoded by the COL1A1 and 
COL1A2 genes, respectively. Several reports have proposed that NF-κB regulates type I 
collagen negatively. NF-κB binds to the site in COL1A1 and COL1A2 promoters, 
leading to inhibition of transcriptional activity [20,21]. Furthermore, activated NF-κB 
suppresses the TGF-β/Smad pathway which promotes fibrosis by inducing inhibitory 
Smad7 protein [22,23]. On the contrary, it has been found that IL-4-mediated activation 
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of the COL1A2 promoter needs cooperation with NF-κB in human embryonic lung 
fibroblasts [24], and COL1A2 promoter activation by TGF-β also requires NF-κB 
binding to its consensus site [25]. These facts imply that NF-κB has dual role in type I 
collagen regulation, presumably depending on cell/tissue circumstances. However, the 
main role of activated NF-κB in keloid fibroblasts seems to be the positive regulation of 
type I collagen accumulation, thus its inhibition by DHMEQ resulted in decreased 
accumulation of type I collagen (Fig. 6). Our result suggests another contribution of 
NF-κB pathway to keloid pathogenesis. 
   A variety of anti-inflammatory agents are known to affect NF-κB activity. For 
example, steroids, the most widely used drugs in keloid treatment, increase the 
expression of IκBα, resulting in the cytoplasmic retention of NF-κB [26,27]. In parallel, 
direct protein-protein interaction between the activated glucocorticoid receptor and 
NF-κB seems to suppress the activation of its pathway [28]. Nonsteroidal 
anti-inflammatory drugs (NSAIDs) such as aspirin and sodium salicylate also suppress 
NF-κB pathway by inhibiting ATP binding to IKKβ [29]. Recently, Zhu et al. have 
reported that aspirin successfully attenuated the cell proliferation and enhanced 
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TNF-α-mediated apoptosis in keloid fibroblasts [30]. However, it is evident that 
steroids and NSAIDs are not specific for IKK nor NF-κB. To the best of our knowledge, 
DHMEQ is the most specific inhibitor that exclusively suppresses NF-κB translocation 
from the cytoplasm to the nucleus. Together, these facts and our results suggest that 
NF-κB-targeted therapy by DHMEQ may be a very attractive approach to the 
management of keloids. 
   One concern about inhibiting the NF-κB pathway in skin tumors including keloids 
is that NF-κB seems to have distinct role in epidermal keratinocytes. It has been 
reported that NF-κB activation is required for normal differentiation of keratinocytes 
[31], and inhibition of the NF-κB pathway in murine epidermis resulted in 
hyperproliferation of keratinocytes and spontaneous development of squamous cell 
carcinomas [32-34]. However, in keloids, not only fibroblasts but also keratinocytes 
seem to be abnormal and contribute to keloid pathogenesis [35,36]. Consistent with this, 
our results of immunohistochemical analysis suggested that NF-κB is activated in 
overlying epidermis of keloid lesion as well (Fig. 2B). Thus, topical treatment with 
NF-κB inhibitor might be ideally suited to keloid, although further assessment of 
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NF-κB function in other type of cells e.g. keratinocytes would be necessary. 
   In conclusion, our results provide a new insight into keloid pathogenesis and 
therapeutic strategy. DHMEQ effectively suppressed the growth of keloid fibroblasts 
and type I collagen accumulation through the inhibition of NF-κB activity, suggesting 
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Figure legends 
Fig. 1 Basal NF-κB DNA-binding activity of normal and keloid fibroblasts. p65 
DNA-binding activity was measured using nuclear extracts isolated from primary 
normal fibroblasts (NF1-4) and keloid fibroblasts (KF1-4) as described in Materials and 
methods. Results are presented as the mean±SD of the data collected in triplicate. 
 
Fig. 2 Representative immunostaining for p65 in normal and keloid tissues. (A, C) 
Normal skin specimen. (B, D) Keloid tissue specimen. (A, B) Original magnification: 
x100; Bars: 100 μm. (C, D) Original magnification: x400; Bars: 50 μm. Similar results 
were obtained in all cases. (E) The number of positive cells in each high power field 
(hpf) was counted under microscope at magnification of x400. Data are presented as the 
mean±SD of six different fields. *P<0.05 vs normal tissue. 
 
Fig. 3 Inhibition of NF-κB DNA-binding activity by DHMEQ. Primary normal 
fibroblasts (NF) or keloid fibroblasts (KF) were treated with DHMEQ for 1 h. Nuclear 
extracts were used for binding assays as described in Materials and methods. Results are 
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shown as percentage relative to the normal skin control. Data are presented as the 
mean±SD of four different lines (NF1-4 and KF1-4). *P<0.05 vs control. 
 
Figure 4 Induction of cell death by DHMEQ. (A) Viability of normal and keloid 
fibroblasts after treatment with various concentrations of DHMEQ for 24 h was 
estimated by WST-based assay. Each point indicates mean±SD of the data collected 
from 6 wells. (B) Cells were exposed to various concentrations of DHMEQ for 24 h, 
and Western blotting for PARP was performed using total cell lysates. Densitometric 
analysis was done and the level of PARP cleavage was expressed as a ratio of cleaved 
band to uncleaved band of untreated cells. Data are presented as mean±SD of four 
different lines (NF1-4 and KF1-4). Similar results were obtained in three independent 
experiments. 
 
Figure 5 Effect of DHMEQ on cell growth. (A) Cells were treated with 5 or 10 μg/ml 
of DHMEQ and cultured for up to 4 d. Each point indicates the mean±SD of the data 
collected from 6 wells. (B) Relative cell number at day 4. Data are presented as 
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mean±SD of four different lines (NF1-4 and KF1-4). *P<0.05 vs normal fibroblasts. 
Similar results were obtained in three independent experiments. 
 
Figure 6 Effect of DHMEQ on type I collagen accumulation. (A) Representative blot 
images. Indicated cells were treated with 5 or 10 μg/ml of DHMEQ for 24 h. Cultured 
media (extracellular type I collagen) or total cell lysates (intracellular type I collagen 
and HSP47) were analyzed by Western blotting. β-actin was used as a loading control. 
(B) Results of densitometric analysis of detected bands. Results are expressed as 
relative levels compared to those of untreated cells. Data are presented as mean±SD of 
four different lines (NF1-4 and KF1-4). *P<0.05 vs untreated cells. Similar results were 
obtained in three independent experiments. 
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